ASCO 2025 will feature the latest advancements in genitourinary cancer and melanoma treatment, focusing on the exciting developments in immunotherapy. Stay updated on the cutting-edge research and ...

Key findings on prostate cancer treatment from the 2025 ASCO meeting are reported by Dr Oliver Sartor from Tulane Medical School in New Orleans. Next, Dr Sartor discusses a phase 1/2 study of ...

Studies presented at the ASCO Annual Meeting 2025 highlighted immunotherapies that may provide new standards of care for certain cancers as well as immunotherapies that are breaking new ground by ...

(UroToday.com) The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, IL between May 30 th and June 3 rd, 2025, was host to a kidney and bladder cancers poster ...

An ASCO provisional clinical opinion offers timely clinical direction to ASCO's membership following publication or presentation of potentially practice-changing data from major studies. This ...

Latest data of InnoCare’s robust oncology pipelines were presented at the 2025 ASCO Annual Meeting, involving the anti-CCR8 antibody ICP-B05 (CM369), the BCL2 inhibitor mesutoclax (ICP-248) and ...

Inside ASCO 2025: Big data drops and a towering campaign By Ayla Ellison, Angus Liu, Gabrielle Masson, Zoey Becker Jun 6, 2025 10:39am The Top Line ASCO 2025 Enhertu Johnson & Johnson ...

Need help accessing your account? Visit ASCO’s Customer Account Assistance page. The Nominating Committee will review all recommendations and announce a slate of candidates for the ASCO Election when ...

At the recent ASCO annual meeting, J&J executive Joshua Bauml explained his company’s strategy for this drug in lung cancer and beyond. By Frank Vinluan on June 05, 2025 6:24 pm.

ASCO discussant Krina Patel, MD, MSc, of the University of Texas MD Anderson Cancer Center in Houston, noted that "ciltacabtagene autoleucel is the first potential functional cure for patients ...

SHANGHAI, June 5, 2025 /PRNewswire/ -- The 2025 ASCO Annual Meeting successfully concluded in Chicago on June 3 (local time). Hengrui Pharma delivered a strong international presence, featuring 15 ...

Vepdegestrant, an oral oestrogen receptor (ER) degrader, improves outcomes in selected patients with ER-positive, HER2-negative advanced breast cancer. In the phase 3 VERITAC-2 trial, presented by ...